Moncef Slaoui

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT.

Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The private company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy.

Monopteros Therapeutics, Inc. manufactures pharmaceuticals.